Trial Profile

Phase I/II, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Durvalumab Monotherapy or in Combination With Tremelimumab in Pediatric Patients With Advanced Solid Tumors and Hematological Malignancies

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 31 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
Indications Anaplastic large cell lymphoma; Diffuse large B cell lymphoma; Haematological malignancies; Hodgkin's disease; Neuroblastoma; Non-Hodgkin's lymphoma; Sarcoma; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors AstraZeneca

08 Mar 2024 This trial has been completed in Italy, as per European Clinical Trials Database record.
21 Feb 2024 Planned End Date changed from 29 Dec 2023 to 30 Dec 2024.
25 Aug 2023 Planned End Date changed from 28 Feb 2023 to 29 Dec 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com